COMMUNIQUÉS West-GlobeNewswire

Medtronic Launches ENCHANT Study to Evaluate ChEVAR Parallel Graft Technique with the Endurant(TM) II/IIs Stent Graft System
24/01/2018
Clinical Study to Investigate the Performance of the ChEVAR Technique in AAA Patients with Short Aortic Necks DUBLIN - January 24, 2018 - Medtronic plc (NYSE: MDT) today announced the launch of the ENCHANT ( EN durant [...]
Fibrocell to Present at Phacilitate Cell and Gene Therapy World 2018
24/01/2018
EXTON, Pa., Jan. 24, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC ), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today [...]
Treatment Commences in Second Patient Cohort in Cynata’s World First Clinical Trial
24/01/2018
MELBOURNE, Australia, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP), is pleased to announce that the first patient in Cohort B has been [...]
Sorrento Therapeutics CAR-T Manufacturing Capacity Expanded With Opening of East Coast GMP Site in Addition to Primary West Coast Facility
24/01/2018
SAN DIEGO, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE ) ("Sorrento"), announced today the expansion of its Good Manufacturing Practices (GMP) CAR-T manufacturing capacity, with an [...]
CASMED Submits FORE-SIGHT® OEM Module 510(k) to FDA
24/01/2018
BRANFORD, Conn., Jan. 24, 2018 (GLOBE NEWSWIRE) -- CAS Medical Systems, Inc. (NASDAQ: CASM ) (CASMED), a leader in non-invasive cerebral oximetry patient monitoring, announces that it has submitted a 510(k) application [...]
VitalHub Subsidiary B Sharp Technologies Signs Strategic Deal to Provide More Children Access to Critical Mental Health Support in Canada
24/01/2018
TORONTO, Jan. 24, 2018 (GLOBE NEWSWIRE) -- B Sharp Technologies, a subsidiary of VitalHub Corp. (“VitalHub”) (TSXV:VHI), has signed a strategic reseller agreement with TELUS Health to distribute a white-labelled version [...]
Helius Medical Technologies and US Army Research Laboratory Launch Additional PoNS® Research
24/01/2018
NEWTOWN, Pa., Jan. 24, 2018 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (TSX: HSM ) (TSX:HSM.WT) (OTCQB:HSDT) (“Helius” or the “Company”), a medical technology company focused on neurological wellness, [...]
Immunovaccine Named to 2018 OTCQX Best 50
24/01/2018
HALIFAX, Nova Scotia, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX: IMV ) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that it has been named to the 2018 OTCQX® Best 50 , a [...]
IntelGenx Initiates Phase 2A Montelukast Versafilm™ Clinical Trial in Alzheimer’s Patients
24/01/2018
SAINT-LAURENT, Quebec, Jan. 24, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX VENTURE:IGX) (OTCQX:IGXT) (the "Company" or "IntelGenx") is pleased to announce that it has initiated the Phase 2a proof of concept (“POC”) [...]
Intellipharmaceutics Provides Operational Update
24/01/2018
TORONTO, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq: IPCI ) (TSX: IPCI ) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, [...]
Santhera Anticipates Receiving a Negative CHMP Opinion on Appeal for Marketing Authorization Application for Raxone® in Duchenne Muscular Dystrophy
24/01/2018
Liestal, Switzerland, January 24, 2018 - Santhera Pharmaceuticals (SIX: SANN) announces that on January 23 it had an oral explanation at the Committee for Medicinal Products for Human Use (CHMP) of the European [...]
Exalenz Bioscience Announces Positive Clinical Trial Results For the Diagnosis of Clinically Significant Portal Hypertension in NASH Patients
24/01/2018
Easy-to-administer, noninvasive BreathID ® test offers multiple advantages over alternative invasive detection methods Potential 2020 entry to an addressable U.S. market of millions of NASH patients MODI’IN, ISRAEL and [...]
Abstract Outlining Pre-Hospital Stroke Study with Diffusion Pharmaceuticals’ TSC To Be Presented at the International Stroke Conference
24/01/2018
CHARLOTTESVILLE, Va., Jan. 24, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN ) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on improving patient outcomes in [...]
BioCorRx Announces Collaboration with the One Day at a Time Program in Philadelphia
24/01/2018
ANAHEIM, Calif., Jan. 24, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company") , a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced a pilot [...]
TG Therapeutics, Inc. Announces Data Presentation at the Upcoming Third Annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2018
24/01/2018
NEW YORK, Jan. 24, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX ), today announced that updated data for ublituximab (TG-1101), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, has been [...]
FDA has approved Faron's Traumakine® IND
24/01/2018
Faron Pharmaceuticals Ltd ("Faron" or the "Company") FDA has approved Faron's Traumakine ® IND TURKU - FINLAND, 24 January 2018 - Faron Pharmaceuticals Ltd ("Faron") (AIM: FARN), the clinical stage biopharmaceutical [...]
miRagen Therapeutics to Present New MRG-106 Phase 1 Clinical Trial Data at the T-Cell Lymphoma Forum
24/01/2018
BOULDER, Colo., Jan. 24, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN ), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced [...]
pSivida Corp. Announces Second Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information
24/01/2018
WATERTOWN, Mass., Jan. 24, 2018 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ: PSDV ) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for treating eye diseases, will report [...]
TRIO Announces Participation in the Avoca Diligent™ Prequalification Platform
24/01/2018
EDMONTON, Alberta, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Translational Research in Oncology (TRIO) is pleased to announce its participation in the Avoca Diligent™ Prequalification Platform . The purpose of this initiative [...]

Pages